Technical Analysis for IMMX - Immix Biopharma, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 200 DMA | Bearish | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Fell Below 20 DMA | Bearish | -7.11% | |
| 200 DMA Support | Bullish | -7.11% | |
| Volume Surge | Other | -7.11% | |
| Bollinger Band Squeeze | Range Contraction | -7.11% | |
| Slingshot Bearish | Bearish Swing Setup | -14.49% | |
| Crossed Above 20 DMA | Bullish | -14.49% | |
| Crossed Above 200 DMA | Bullish | -14.49% | |
| MACD Bullish Signal Line Cross | Bullish | -14.49% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | about 11 hours ago |
| Down 5% | about 11 hours ago |
| Fell Below Previous Day's Low | about 11 hours ago |
| 200 DMA Resistance | about 14 hours ago |
| 10 DMA Resistance | about 14 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/01/2023
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. It is developing IMX-110 that is in Phase Ib/IIa clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. The company has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase Ib clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc. was incorporated in 2012 and is based in Los Angeles, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Solid Tumors Autoimmune Disease Inflammation Colorectal Cancer Sarcoma Ulcerative Colitis Abdominal Pain Crohn's Disease Soft Tissue Sarcoma Beigene
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Solid Tumors Autoimmune Disease Inflammation Colorectal Cancer Sarcoma Ulcerative Colitis Abdominal Pain Crohn's Disease Soft Tissue Sarcoma Beigene
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.4499 |
| 52 Week Low | 0.68 |
| Average Volume | 122,546 |
| 200-Day Moving Average | 1.95 |
| 50-Day Moving Average | 2.24 |
| 20-Day Moving Average | 2.00 |
| 10-Day Moving Average | 1.94 |
| Average True Range | 0.21 |
| RSI | 42.86 |
| ADX | 13.75 |
| +DI | 23.07 |
| -DI | 20.70 |
| Chandelier Exit (Long, 3 ATRs) | 1.75 |
| Chandelier Exit (Short, 3 ATRs) | 2.38 |
| Upper Bollinger Bands | 2.26 |
| Lower Bollinger Band | 1.74 |
| Percent B (%b) | 0.18 |
| BandWidth | 26.22 |
| MACD Line | -0.09 |
| MACD Signal Line | -0.10 |
| MACD Histogram | 0.0043 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.04 | ||||
| Resistance 3 (R3) | 2.05 | 2.00 | 2.01 | ||
| Resistance 2 (R2) | 2.00 | 1.94 | 1.99 | 1.99 | |
| Resistance 1 (R1) | 1.91 | 1.91 | 1.89 | 1.90 | 1.98 |
| Pivot Point | 1.86 | 1.86 | 1.84 | 1.85 | 1.86 |
| Support 1 (S1) | 1.77 | 1.80 | 1.74 | 1.76 | 1.68 |
| Support 2 (S2) | 1.72 | 1.77 | 1.71 | 1.67 | |
| Support 3 (S3) | 1.63 | 1.72 | 1.65 | ||
| Support 4 (S4) | 1.62 |
